SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is facing significant downward volatility as the market digests broader semiconductor sector rotation and heavy institutional selling, despite the company reporting record revenue and strong AI-driven guidance. While some investors view the pullback as a buying opportunity given the company's central role in the AI infrastructure buildout, the community remains divided, with active debates centered on whether recent price action reflects a structural correction in the AI bubble or a temporary liquidity-driven hunt.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is rallying as institutional investors and high volume suggest a significant accumulation phase, leading the community to discuss a potential short squeeze as the stock breaks through key resistance levels. Traders are increasingly bullish, pointing to the company's strong cash position, profitability, and leadership in the agentic AI and orchestration sector as primary drivers for the sustained upward momentum.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a bullish technical breakout above key resistance levels, with investors actively discussing potential institutional accumulation ahead of upcoming BLA filing milestones. Community sentiment remains focused on the company's clear clinical progress, manufacturing alignment with the FDA, and speculative interest surrounding a major sector buyout.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is facing intense downward pressure following a weak earnings report that disappointed investors with declining revenue, despite some community interest in their pivot toward higher-margin systems integration and long-term data center infrastructure. While bulls are pinning hopes on future rack integration growth and new facility expansions, the community remains deeply divided, with many actively discussing the lack of growth visibility and management's perceived failure to capitalize on the AI infrastructure boom.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors digest the impact of recent acquisitions, with the community actively debating whether the company's long-term turnaround strategy justifies its current price action amid lack of formal earnings calls. While some participants are wary of dilution and poor sentiment, others view the stock as a deeply undervalued, long-term opportunity driven by strong institutional backing and a seasoned leadership team.

Workday, Inc. engages in the development of enterprise cloud applications for finance and human resources. The firm delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. It operates through the Cloud Applications segment. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday stock is trending following reports that private equity firm Silver Lake is in early-stage talks to acquire the company, triggering significant market volatility and multiple trading halts. While the market is buzzing over the potential for a massive leveraged buyout, investors remain divided, with some questioning the feasibility of the rumored valuation and others debating whether this signals a sector-wide recovery for software companies.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is trending as investors weigh significant legislative developments surrounding the Clarity Act against new institutional partnerships, including a strategic IBM patent acquisition. The stock is seeing heightened volatility and accumulation as the community debates whether the upcoming earnings report and potential regulatory breakthroughs will trigger a sustained breakout or if broader market pressures will force a retest of lower support levels.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is facing mixed sentiment as investors weigh strong customer growth and recent strategic expansion against concerns over CFO turnover and broader regional credit risks. While some community members view the current price action as an accumulation opportunity, others are exercising caution ahead of upcoming earnings and monitoring the impact of new leadership on the company's long-term international expansion.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and intense community debate as shareholders react to an accelerated lockup expiration, sparking fears of a potential sell-off. Investors remain polarized, with bulls pointing to the fund's exposure to high-profile AI and space companies like Anthropic and SpaceX as long-term catalysts, while bears warn that the stock continues to trade at a substantial premium to its net asset value.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is trending as investors monitor ongoing institutional positioning and short interest dynamics while awaiting news regarding CVS Caremark formulary inclusion. The community remains divided, with debates centered on whether recent volatility reflects a buying opportunity ahead of potential catalysts or broader concerns over the company's commercial execution and competitive landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates

EyePoint (EYPT) delivered earnings and revenue surprises of -18.48% and +102.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?

Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to Decline

EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eyepoint Pharmaceuticals Q1 Earnings Call Highlights

EyePoint Pharmaceuticals (NASDAQ:EYPT) executives told investors the company is approaching what they described as a "pivotal inflection point" for its lead program, DURAVYU, with phase III wet age-related macular degeneration (wet AMD) top-line data expected beginning mid-year and a rapidly enrolli...

EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint (EYPT) delivered earnings and revenue surprises of -25.32% and +132.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have...

Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells $36,555.00 in Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold...

Insider Selling: Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells 2,437 Shares of Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed...

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.48
Prev Close	$13.53
Open	$13.59
Dividend Yield	0.00%
50-Day Moving Average	$13.09
Beta	1.24
Avg. Volume	1.54M
PE Ratio	-3.61

52-Week High	$19.11
52-Week Low	$9.65
Market Capitalization	$1.17B
EPS (Annual)	-$3.17
Price to Book	6.91
Revenue Per Employee	$146,593.46

Feed

News

Sentiment

Earnings

Fundamentals

Info